Evaluating and Supporting Patients Presenting with Cognitive Symptoms Following COVID
“This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention.”
The fully captioned video and edited transcript will be posted within the next few days.
This COCA Call will be held on Friday, March 27, 2020
During this COCA Call, presenters will discuss post-COVID conditions (PCC), an umbrella term for the wide range of health consequences that are present four or more weeks after infection with SARS-CoV-2, which includes long COVID. Cognitive symptoms, often described by patients as “brain fog”, are frequently reported following SARS-CoV-2 infection. The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has recently published a Multi-Disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Cognitive Symptoms in PCC that provides practical guidance to clinicians in the assessment and treatment of individuals with cognitive symptoms and a history consistent with PCC. The burden of PCC is expected to reflect the disproportionate burden of infection by race, ethnicity, and socioeconomic status and to highlight ongoing inequities in health care. The Health Equity Work Group of the AAPM&R has developed guidance to highlight the central role that principles of diversity, equity, and inclusion play in delivering quality health care.
Jennifer Cope, MD, MPH
Post-COVID Conditions Team
Epidemiology Task Force
Centers for Disease Control and Prevention
Michelle Haddad, PhD
Director of Post-COVID Neuropsychology Clinic
Director of Inpatient Neuropsychology
Departments of Rehabilitation Medicine & Neurology
Emory University School of Medicine
Jeffrey S. Fine, MD, FAAPMR
Associate Professor and Vice Chair, Rusk Rehabilitation
Dept of Rehabilitation Medicine and Dept of Medicine
NYU Langone Health
Talya K. Fleming, MD
Assistant Professor and Medical Director
JFK Johnson Rehabilitation Institute
Dept of Physical Medicine and Rehabilitation
Hackensack Meridian Medicine
Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.
Thursday, May 5, 2022,
2:00 PM – 3:00 PM ET
US: +1 669 254 5252
or +1 646 828 7666
or +1 551 285 1373
or +1 669 216 1590
US: +16692545252,,1603316732#,,,,*828356# or +16468287666,,1603316732#,,,,*828356#
Webinar ID: 160 331 6732Add to Calendar
Registration is not required.
Date: Thursday, May 5, 2022
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar begins, please click the link below to join:
Webinar ID: 160 331 6732
Dial-in US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590
One-tap mobile: US: +16692545252,,1603316732#,,,,*828356# or +16468287666,,1603316732#,,,,*828356#
International numbers available: https://www.zoomgov.com/u/a6PCpGoreexternal icon
- Describe cognitive symptoms associated with post-COVID conditions (PCC).
- Determine which clinical assessments and tests are needed for an individual patient with cognitive symptoms.
- Apply health equity considerations to clinical care, activity management, and reconditioning of long COVID patients.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
- AAPM&R Guidance Statement: https://onlinelibrary.wiley.com/doi/10.1002/pmrj.12745external icon
- Presentation tables (also available in PowerPoint slidesppt iconexternal icon), includes recommendations, screening tools, strategies, health equity considerations and more: https://www.aapmr.org/docs/default-source/news-and-publications/covid/cognitive-symptoms-guidance-tables-030222.pdf?sfvrsn=e38e287c_0pdf iconexternal icon
- AAPMR website with additional resources: https://www.aapmr.org/members-publications/covid-19/multidisciplinary-quality-improvement-initiativeexternal icon
To receive continuing education (CE) for WC4520-050522 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Evaluating and Supporting Patients Presenting with Cognitive Symptoms Following COVID, Thursday, May 5, 2022, please visit TCEO and follow these 9 Simple Steps by Monday, June 6, 2022.
To receive continuing education (CE) for WD4520-050522 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Evaluating and Supporting Patients Presenting with Cognitive Symptoms Following COVID, Thursday, May 5, 2022, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, June 7, 2022, and Friday, June 7, 2024
In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-22-032-L04-P and enduring JA4008229-0000-22-033-H04-P.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at firstname.lastname@example.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, with the exception of Dr. Talya Fleming who would like to disclose that she received a research grant from NuStep and served as co-principal investigator for Stroke Rehabilitation Clinical Research Trial. All grant funds are received and managed by hospital organization.
All of the relevant financial relationships listed for this individual has been mitigated.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:email@example.com
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.